Skip to main content

Myriad Genetics EndoPredict Test

Myriad Genetics has launched the EndoPredict test, a second-generation test for assessing the 10-year risk of disease recurrence in patients with ER+ HER2- early-stage breast cancer. The test includes proliferation-related genes and hormone receptor-related genes to provide clinicians with an accurate assessment of early and late risk recurrence, the company said. It uses this information to definitively classify patients as low or high risk, which helps clinicians make therapy decisions going forward.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.